170 related articles for article (PubMed ID: 31824148)
21. 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor.
Bazzi R; Bradshaw TD; Rowlands JC; Stevens MF; Bell DR
Toxicol Appl Pharmacol; 2009 May; 237(1):102-10. PubMed ID: 19265716
[TBL] [Abstract][Full Text] [Related]
22. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
Hose CD; Hollingshead M; Sausville EA; Monks A
Mol Cancer Ther; 2003 Dec; 2(12):1265-72. PubMed ID: 14707267
[TBL] [Abstract][Full Text] [Related]
23. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
Leong CO; Suggitt M; Swaine DJ; Bibby MC; Stevens MF; Bradshaw TD
Mol Cancer Ther; 2004 Dec; 3(12):1565-75. PubMed ID: 15634650
[TBL] [Abstract][Full Text] [Related]
24. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.
Brantley E; Patel V; Stinson SF; Trapani V; Hose CD; Ciolino HP; Yeh GC; Gutkind JS; Sausville EA; Loaiza-Pérez AI
Anticancer Drugs; 2005 Feb; 16(2):137-43. PubMed ID: 15655410
[TBL] [Abstract][Full Text] [Related]
25. Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.
Abuzaid H; Abdelrazig S; Ferreira L; Collins HM; Kim DH; Lim KH; Kam TS; Turyanska L; Bradshaw TD
ACS Omega; 2022 Jun; 7(25):21473-21482. PubMed ID: 35785302
[TBL] [Abstract][Full Text] [Related]
26. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.
Monks A; Harris E; Hose C; Connelly J; Sausville EA
Mol Pharmacol; 2003 Mar; 63(3):766-72. PubMed ID: 12606787
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of some new benzoxazole derivatives and investigation of their anticancer activities.
Osmaniye D; Korkut Çelikateş B; Sağlık BN; Levent S; Acar Çevik U; Kaya Çavuşoğlu B; Ilgın S; Özkay Y; Kaplancıklı ZA
Eur J Med Chem; 2021 Jan; 210():112979. PubMed ID: 33183865
[TBL] [Abstract][Full Text] [Related]
28. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.
Loaiza-Pérez AI; Trapani V; Hose C; Singh SS; Trepel JB; Stevens MF; Bradshaw TD; Sausville EA
Mol Pharmacol; 2002 Jan; 61(1):13-9. PubMed ID: 11752201
[TBL] [Abstract][Full Text] [Related]
29. Encapsulation of the Dinuclear Trithiolato-Bridged Arene Ruthenium Complex Diruthenium-1 in an Apoferritin Nanocage: Structure and Cytotoxicity.
Petruk G; Monti DM; Ferraro G; Pica A; D'Elia L; Pane F; Amoresano A; Furrer J; Kowalski K; Merlino A
ChemMedChem; 2019 Mar; 14(5):594-602. PubMed ID: 30674089
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).
Bradshaw TD; Chua MS; Orr S; Matthews CS; Stevens MF
Br J Cancer; 2000 Jul; 83(2):270-7. PubMed ID: 10901382
[TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw TD; Chua MS; Browne HL; Trapani V; Sausville EA; Stevens MF
Br J Cancer; 2002 Apr; 86(8):1348-54. PubMed ID: 11953897
[TBL] [Abstract][Full Text] [Related]
32. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.
Rowland LK; Campbell PS; Mavingire N; Wooten JV; McLean L; Zylstra D; Thorne G; Daly D; Boyle K; Whang S; Unternaehrer J; Brantley EJ
J Cell Biochem; 2019 Apr; 120(4):6004-6014. PubMed ID: 30450577
[TBL] [Abstract][Full Text] [Related]
33. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds.
Bradshaw TD; Stevens MF; Westwell AD
Curr Med Chem; 2001 Feb; 8(2):203-10. PubMed ID: 11172675
[TBL] [Abstract][Full Text] [Related]
34. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
[TBL] [Abstract][Full Text] [Related]
35. Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives.
Shi DF; Bradshaw TD; Chua MS; Westwell AD; Stevens MF
Bioorg Med Chem Lett; 2001 Apr; 11(8):1093-5. PubMed ID: 11327598
[TBL] [Abstract][Full Text] [Related]
36. In vitro cytotoxicity of Phortress against colorectal cancer.
Mukherjee A; Martin SG
Int J Oncol; 2006 Nov; 29(5):1287-94. PubMed ID: 17016663
[TBL] [Abstract][Full Text] [Related]
37. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe?
Bradshaw TD; Trapani V; Vasselin DA; Westwell AD
Curr Pharm Des; 2002; 8(27):2475-90. PubMed ID: 12369945
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
Kang HJ; Kim HJ; Kwon SH; Kang BD; Eling TE; Lee SH; Bae I
Cancer Chemother Pharmacol; 2008 Sep; 62(4):689-97. PubMed ID: 18074135
[TBL] [Abstract][Full Text] [Related]
39. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
Bradshaw TD; Wrigley S; Shi DF; Schultz RJ; Paull KD; Stevens MF
Br J Cancer; 1998 Mar; 77(5):745-52. PubMed ID: 9514053
[TBL] [Abstract][Full Text] [Related]
40. Apoferritin as an ubiquitous nanocarrier with excellent shelf life.
Dostalova S; Vasickova K; Hynek D; Krizkova S; Richtera L; Vaculovicova M; Eckschlager T; Stiborova M; Heger Z; Adam V
Int J Nanomedicine; 2017; 12():2265-2278. PubMed ID: 28392686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
